3189 results for «750»
3189 results
Drug-eluting balloon in calcified lesions and complex lesions
28 Feb 2026 – From Euro4C Annual Meeting 2026
This session explores the application of drug-eluting balloons (DCB) in managing calcified and complex coronary lesions. Emphasis is placed on identifying appropriate lesions for a DCB-only strategy, the critical role of vessel preparation prior to drug delivery, and the long-term physiological assessment following treatment, supported by...
Mitral and aortic transcatheter valve-in-valve intervention - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
Live case
An 83-year-old male with AF, CKD (stage 3A), preserved LV function, and a history of AVR (27 mm Magna Ease) and MVR (33 mm Magna) in 2014 presented with symptomatic stenosis of the mitral bioprosthesis. A Sapien 3 valve was implanted in the Magna mitral...
TEER in complex tricuspid regurgitation - LIVE case
14 Feb 2026 – From PCR Tokyo Valves 2026
A 79-year-old male with permanent AF, prior colorectal and prostate cancer, and a Mosaic bioprosthetic mitral valve implanted in 2016, presented with torrential tricuspid regurgitation and preserved LV function.
Three G5 clips were implanted: two anteroseptal (1 XTW and 1 XT) and one posteroseptal XTW.
LIVE Educational Case...
Primary mitral TEER in small anatomy - LIVE case
15 Feb 2026 – From PCR Tokyo Valves 2026
An 89-year-old male with diabetes mellitus, hypertension, chronic kidney disease (eGFR: 46), and CAD with a history of NSTEMI and CTO of the RCA, presented with symptomatic primary mitral regurgitation (P1–P2 prolapse) and preserved LV function (56%).
One Pascal ACE device was implanted.
LIVE Educational Case from Nagoya...
Mechanical circulatory support protected PCI in complex calcified patients
28 Feb 2026 – From Euro4C Annual Meeting 2026
Explore the critical role of mechanical circulatory support with Impella in complex calcified patients undergoing PCI. This session delves into patient selection criteria, reviews the latest evidence, and discusses strategies to prevent and manage device-related complications, supported by case presentations focusing on imaging analysis, vascular access...
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
Pi-Cardia’s ShortCut™ Becomes First Leaflet Modification Technology to Receive CMS NTAP for Valve-in-Valve TAVR
06 Aug 2025
In Person in Paris and online EuroPCR 2022 celebrates the best of both worlds
09 May 2022
EuroPCR is celebrating being back home in Paris, in-person, for the first time in 3 years. This year’s international Course will see both a complete on-site programme and a full digital experience, bringing the community together to share and learn.
Meril Life Sciences presents one-year outcomes from the LANDMARK randomized controlled trial at PCR London Valves 2025
16 Nov 2025
